Virtue Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Virtue Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,121	Closed	-$464K	–	308
2025 Q3	$464K	Buy	+4,121	New	+$1.68M	0.07%	184
2018 Q4	–	Sell	-41,142	Closed	-$3.6M	–	97
2018 Q3	$3.6M	Buy	41,142 +25,865	+169%	+$2.6M	0.76%	42
2018 Q2	$1.5M	Buy	15,277 +7,413	+94%	+$735K	0.73%	36
2018 Q1	$754K	Buy	7,864 +4,531	+136%	+$584K	0.4%	78
2017 Q4	$423K	Buy	+3,333	New	+$419K	0.24%	117

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Virtue Capital Management's ALNY Position: Q4 2025 in Review

Virtue Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 4,121 shares — an estimated $464K sold.

Virtue Capital Management first reported a position in ALNY in Q4 2017 and held it in 5 quarters. The position peaked at $3.6M in Q3 2018. 849 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Virtue Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Virtue Capital Management sold 4,121 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $464K.
Virtue Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Virtue Capital Management's Alnylam Pharmaceuticals position peaked at $3.6M in Q3 2018.
849 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Virtue Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.